O'key 144a (61HD) Quote

Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.

Marc loved your ides

I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........

Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
[yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]

In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

This is DUE DILIGENCE! Thank you Free Fannie.

https://x.com/freefannie/status/1878655047715991552?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ

That Xeriant PR excellently written with bullshit:

""After successfully completing 75% of the demanding NFPA 286 test," meaning = "after failing the NFPA 286 test by missing 25% of the approval target testing requirement,"

"the Company used the data to make several key

You were actually partially right....BMXI has filed some SEC documents, some necessary (Form 1-A), some unnecessary (Form 4). And they do summarize a lot of the stuff that I think are fabrications....their production, mining operations, etc. Time will tell, but I think a lot of it (and probably

Jim wrote a blurb about seeking more US business.

Help you out any? 🤨

Any news or updates?

.0915 by Thursday....... 

Remember GBM was redefined during the trial, thus some who were treated then had other forms of brain cancer. I believe the least we'll see in our label is brain cancer. Certainly GBM may be the deadliest of them, but treatment should work in all of them.

According to Google, GBM ha

You are right about the crafty, evil, smart. Authoritarian methods have been in full view
in capturing America. While we work to do the right things they plot to capture the lot.

If there weren’t suckers born every minute, there wouldn’t be POSRMX bag holders down as much as 99%, and there sure as hell wouldn’t be anybody believing there is a pipeline of products.






.

Your "closer" keeps getting extended. Then again extended. Then again extended. -- Consider that end. Now expired, horizon end now reached, and the view clarifies and we see it to be your desperation from years ago ongoing still, to pump this at any expense, where you attempt to instill FOMO to hold

He would smother any question with words.

$HMBL Sorry HMBL investors. XTIA now broke the record 2.7B share volume traded before the reverse split.



https://x.com/shawonsarker84/status/1878696680088019193?t=rZlhkn2Jos4vWKxxQgXGfA&s=19

https://www.energy.senate.gov/hearings/2025/1/hearing-to-consider-the-nomination-of-mr-chris-wright-to-be-secretary-of-energy

https://www.commerce.senate.gov/2025/1/full-committee-nomination-hearing_2#:~:text=U.S.%20Senator%20Ted%20Cruz%20(R,Wednesday%2C%20January%2015%2C%20

Oh noooooo.....

OTC filings and attorney statements. my error.

Point that it is on you to prove your claim, that:
"There's no contract employees. There's no production shafts."

Likewise for the company to do so, as we wait for an audit, apparently indefinitely.

I

Definitely excited to hear about batch 5. I believe we should hear news very soon. if they began batch 5 immediately after batch 4 then 5 is overdue.

And in light of last week's PR about Darwin's Bark Dragline silk, I'm expecting KBLB to have the attention of the DOD once again.

Too bad no mention of the degree of brain atrophy of the Blar treated patients reverting to close to normal aging compared to the MAB treated patients having accelerated rate of atrophy.

To me this is a bio marker that sets the two therapies at extreme ends of the plus minus continuum